Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yong-Joon | - |
dc.contributor.author | Park, Jin Kyu | - |
dc.contributor.author | Uhm, Jae-Sun | - |
dc.contributor.author | Kim, Jong-Yun | - |
dc.contributor.author | Pak, Hui-Nam | - |
dc.contributor.author | Lee, Moon-Hyoung | - |
dc.contributor.author | Sung, Jung-Hoon | - |
dc.contributor.author | Joung, Boyoung | - |
dc.date.accessioned | 2021-07-30T05:21:29Z | - |
dc.date.available | 2021-07-30T05:21:29Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-01 | - |
dc.identifier.issn | 0167-5273 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4393 | - |
dc.description.abstract | Background: The efficacy of oral anticoagulation therapy (OAT) has not been revealed in atrial fibrillation (AF) patients with newly diagnosed cancers. This study evaluated the thromboembolic and bleeding events in AF patients with malignancies according to OAT. Methods and results: In 2168 consecutive non-valvular AF patients with newly diagnosed malignancies, we analyzed the composite endpoints including major adverse cardiac events (MACEs) and major bleeding. Based on a propensity score matching, two groups with 690 matched pairs were created. Patient baseline characteristics were comparable between the matched groups. During a follow-up period of 3.9 +/- 2.8 years, 72 (10%) and 65 (9%) patients had MACEs in the propensity score-matched OAT+ and OAT-groups, respectively (p = 0.461). There was no significant difference in the major bleeding (10% vs. 8%, p = 0.300) and composite endpoints (18% vs. 16%, p = 0.181) between OAT+ and OAT-patients. During the first year after the cancer diagnosis, 66 (48%) MACEs, 52 (41%) major bleedings, and 116 (49%) composite end points of all events occurred. The optimal international normalized ratio (2.0 to 3.0) level was achieved in only 85 (12%) patients. However, 1 year after cancer diagnosis, OAT+ patients with the target therapeutic range of ˃= 60% demonstrated better cumulative survival free of composite end point than OAT-patients (p= 0.026). Conclusion: During the first year after the cancer diagnosis, OAT did not improve the composite end point because of poor INR control caused by cancer treatment. However, after 1 year after diagnosis of cancer, optimal anticoagulation significantly reduced the composite end point. (C) 2015 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.title | Bleeding risk and major adverse events in patients with cancer on oral anticoagulation therapy | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Jin Kyu | - |
dc.identifier.doi | 10.1016/j.ijcard.2015.10.166 | - |
dc.identifier.scopusid | 2-s2.0-84952673549 | - |
dc.identifier.wosid | 000367007200097 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CARDIOLOGY, v.203, pp.372 - 378 | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 203 | - |
dc.citation.startPage | 372 | - |
dc.citation.endPage | 378 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.subject.keywordPlus | RECURRENT VENOUS THROMBOEMBOLISM | - |
dc.subject.keywordPlus | ATRIAL-FIBRILLATION | - |
dc.subject.keywordPlus | LUNG-CANCER | - |
dc.subject.keywordPlus | STROKE PREVENTION | - |
dc.subject.keywordPlus | COLORECTAL-CANCER | - |
dc.subject.keywordPlus | WARFARIN THERAPY | - |
dc.subject.keywordPlus | LONG-TERM | - |
dc.subject.keywordPlus | POPULATION | - |
dc.subject.keywordPlus | PREVALENCE | - |
dc.subject.keywordPlus | COMPLICATIONS | - |
dc.subject.keywordAuthor | Atrial fibrillation | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | Anticoagulation | - |
dc.subject.keywordAuthor | Stroke | - |
dc.subject.keywordAuthor | Hemorrhage | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.